I. A. Babitskaya

I. A. Babitskaya

Auto-generated profile, based on publicly available information

I. A. Babitskaya

The S. Fyodorov Eye Microsurgery Federal State Institution

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2021 in Ophthalmology in Russia
Verified
Journal Article
Open access
PDF file
ADA. V. Doga
A. V. Doga
NMN. V. Maychuk
N. V. Maychuk
IMI. A. Mushkova
I. A. Mushkova
IBI. A. Babitskaya
I. A. Babitskaya
In the Russian literature, there are only a few works that summarize their own experience in the treatment of recurrent corneal erosion (RCE) in a limited group of patients, which actualizes further research in this direction.Objective: to develop and evaluate the clinical effectiveness of an integrated approach to the management of patients with RCE.Patients and methods. 69 patients (69 eyes) with RCE and a disease duration of at least two years, who were divided into 3 groups according to the frequency of relapses: group 1 (12 people) — episodes of RCE no more than 2–4 times a year; Group 2 (19 people) — RCE episodes no more than once a month; Group 3 (38 people) — RCE episodes more than 2 times a month. All patients were cured by pharmacological support, if conservative therapy was ineffective (1 relapse during treatment within 1 month), phototherapeutic keratectomy (PTK) was performed with the application of a bandage contact lens and the appointment of pathogenetically-oriented treatment for up to 1 year. The average follow-up period was 28.6 ± 6.1 months.Results and discussion. In group 1, during the entire period of observation, RCE was compensated by the therapy, in the other groups, the effectiveness was lower, which in 41 (59.4 %) cases required the implementation of PTK. There were no relapses of corneal erosion after PTK with subsequent pathogenetically-oriented therapy, including heparin-containing medications in instillation (CHYLOPARIN-KOMOD®) and ointment forms (PARIN-POS®) for 1 year.Conclusion. The high effectiveness of PTK with subsequent pathogenetically-oriented pharmacological support may be the basis for a broader recommendation of this method in patients with RCE and a relapse rate of more than 1 time a month.